Inhibition of ACC1 Diminishes the Malignant Phenotype of Hepatobiliary Cancers In Vitro
Main Article Content
Abstract
Hepatobiliary cancers are a collection of malignancies arising from liver and biliary tract cells. These cancers have high anatomical proximity, overlapping symptoms, and share common risk factors. Hepatobiliary cancers are generally rare and often lack effective treatment options due to late diagnoses and limited treatment efficacy. These cancers tend to be highly aggressive, which limits treatment options for patients, especially since diagnosis often occurs at later stages of disease progression. Chronic inflammation is the most significant risk factor for developing these malignancies. Inflammation alters cellular metabolism, which gives them unique metabolism characteristics that enhance their survival and increase malignancy. Acetyl-Coa-carboxylase (ACC) is a metabolic enzyme responsible for the carboxylation of acetyl-CoA (AC) into malonyl-CoA (MC). MC is used in de novo fatty acid synthesis, an upregulated process in human cancers. Acetyl-Coa-carboxylase 1 (ACC1), in particular, is the first rate-limiting step for de novo lipogenesis. Here we delve into the effect of ACC1 inhibition on the malignant phenotypes of hepatobiliary cancers. Our results showed that knockdown of ACC1 slowed proliferation and migration, reduced spheroid formation, and altered cell cycle progression and protein expression in hepatobiliary cancers. In conclusion, our study suggests that ACC1 may contribute to hepatobiliary cancers' malignancy and may be utilized as a therapeutic target for treating such diseases.
Keywords:
hepatobiliary cancers, Acetyl-Coa-carboxylase, ACC1, cancer metabolism, malignant phenotype
Article Details
How to Cite
JACQUET, Noel et al.
Inhibition of ACC1 Diminishes the Malignant Phenotype of Hepatobiliary Cancers In Vitro.
Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/5759>. Date accessed: 12 dec. 2024.
doi: https://doi.org/10.18103/mra.v12i11.5759.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Groen P. Biliary Tract Cancers | New England Journal of Medicine. The New England Journal of Medicine. 1999;Vol. 341 No. 18.
doi:10.1056/NEJM199910283411807
2. Krasinskas A. Cholangiocarcinoma - ClinicalKey. Surgical Pathology Clinics. 2018;11(2):403-429.
3. Gallbladder cancer | Nature Reviews Disease Primers. Accessed August 28, 2024. https://www.nature.com/articles/s41572-022-00398-y
4. Pant K, Gradilone SA. Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. Technology in Cancer Research & Treatment. Published online May 12, 2022. doi:10.1177/15330338221097203
5. Y W, J L, Y X, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(9). doi:10.1200/JCO.2012.41.5984
6. Satake T, Morizane C, Rikitake R, Higashi T, Okusaka T, Kawai A. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57(11):890-901. doi:10.1007/s00535-022-01920-5
7. Yu J, Shi L, Lin W, Lu B, Zhao Y. UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer. Biochem Pharmacol. 2020;172:113745. doi:10.1016/j.bcp.2019.113745
8. Yu J, Shi L, Shen X, Zhao Y. UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals. Biochem Pharmacol. 2019;166:174-184. doi:10.1016/j.bcp.2019.05.017
9. World Health Statistics. Accessed August 28, 2024. https://www.who.int/data/gho/data/themes/world-health-statistics
10. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-588. doi:10.1038/s41575-020-0310-z
11. Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Sig Transduct Target Ther. 2020;5(1):1-19. doi:10.1038/s41392-020-00324-2
12. Park JH, Pyun WY, Park HW. Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells. 2020;9(10):2308. doi:10.3390/cells9102308
13. Cholangiocarcinoma (bile duct cancer) - Symptoms and causes. Mayo Clinic. Accessed October 2, 2024. https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/symptoms-causes/syc-20352408
14. Ilyas SI, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterol-ogy. 2013;145(6):1215-1229. doi:10.1053/j.gastro.2013.10.013
15. Cancer statistics for the year 2020: An overview - PubMed. Accessed October 9, 2024. https://pubmed.ncbi.nlm.nih.gov/33818764/
16. Global Cancer Observatory. Accessed August 28, 2024. https://gco.iarc.who.int/en
17. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
18. Gravitz L. Liver cancer. Nature. 2014;516(7529):S1-S1. doi:10.1038/516S1a
19. Cen W, Li J, Tong C, et al. Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2. J Cancer. 2021;12(12):3448-3457. doi:10.7150/jca.55627
20. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in Liver Disease. 2017;21(1):1-20. doi:10.1016/j.cld.2016.08.001
21. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. European Journal of Cancer. 2022;161:108-118. doi:10.1016/j.ejca.2021.11.023
22. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147-R1151. doi:10.1016/j.cub.2017.09.019
23. Cancer-related inflammation. Accessed August 28, 2024. https://air.unimi.it/handle/2434/145688
24. Cellular fatty acid metabolism and cancer - PubMed. Accessed August 28, 2024. https://pubmed.ncbi.nlm.nih.gov/23791484/
25. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(5):400-410, 413.
26. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
27. Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141-162. doi:10.1038/s41573-021-00339-6
28. The Heterogeneity of Liver Cancer Metabolism. In: Le A, ed. The Heterogeneity of Cancer Metabolism. Springer International Publishing; 2021:127-136. doi:10.1007/978-3-030-65768-0_9
29. Wang Y, Yu W, Li S, Guo D, He J, Wang Y. Acetyl-CoA Carboxylases and Diseases. Front Oncol. 2022;12:836058. doi:10.3389/fonc.2022.836058
30. Luo DX, Tong DJ, Rajput S, et al. Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential. Recent Patents on Anti-Cancer Drug Discovery. 7(2):168-184. doi:10.2174/157489212799972918
31. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models - PubMed. Accessed October 9, 2024. https://pubmed.ncbi.nlm.nih.gov/27643638/
32. Schug ZT, Vande Voorde J, Gottlieb E. The metabolic fate of acetate in cancer. Nat Rev Cancer. 2016;16(11):708-717. doi:10.1038/nrc.2016.87
33. Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006;66(10):5287-5294. doi:10.1158/0008-5472.CAN-05-1489
34. Razumilava N, Gores GJ. Cholangiocarcinoma. The Lancet. 2014;383(9935):2168-2179. doi:10.1016/S0140-6736(13)61903-0
35. Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280. doi:10.1038/nrgastro.2016.51
36. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.
37. Liver cancer - Symptoms and causes. Mayo Clinic. Accessed October 2, 2024. https://www.mayoclinic.org/diseases-conditions/liver-cancer/symptoms-causes/syc-20353659
38. Liver Cancer: Symptoms, Signs, Causes & Treatment. Cleveland Clinic. Accessed October 2, 2024. https://my.clevelandclinic.org/health/diseases/9418-liver-cancer
39. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(5):400-410, 413.
40. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200
41. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism. 2016;23(1):27-47. doi:10.1016/j.cmet.2015.12.006
42. GEPIA (Gene Expression Profiling Interactive Analysis). Accessed August 28, 2024. http://gepia.cancer-pku.cn/index.html
doi:10.1056/NEJM199910283411807
2. Krasinskas A. Cholangiocarcinoma - ClinicalKey. Surgical Pathology Clinics. 2018;11(2):403-429.
3. Gallbladder cancer | Nature Reviews Disease Primers. Accessed August 28, 2024. https://www.nature.com/articles/s41572-022-00398-y
4. Pant K, Gradilone SA. Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. Technology in Cancer Research & Treatment. Published online May 12, 2022. doi:10.1177/15330338221097203
5. Y W, J L, Y X, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(9). doi:10.1200/JCO.2012.41.5984
6. Satake T, Morizane C, Rikitake R, Higashi T, Okusaka T, Kawai A. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57(11):890-901. doi:10.1007/s00535-022-01920-5
7. Yu J, Shi L, Lin W, Lu B, Zhao Y. UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer. Biochem Pharmacol. 2020;172:113745. doi:10.1016/j.bcp.2019.113745
8. Yu J, Shi L, Shen X, Zhao Y. UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals. Biochem Pharmacol. 2019;166:174-184. doi:10.1016/j.bcp.2019.05.017
9. World Health Statistics. Accessed August 28, 2024. https://www.who.int/data/gho/data/themes/world-health-statistics
10. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-588. doi:10.1038/s41575-020-0310-z
11. Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Sig Transduct Target Ther. 2020;5(1):1-19. doi:10.1038/s41392-020-00324-2
12. Park JH, Pyun WY, Park HW. Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells. 2020;9(10):2308. doi:10.3390/cells9102308
13. Cholangiocarcinoma (bile duct cancer) - Symptoms and causes. Mayo Clinic. Accessed October 2, 2024. https://www.mayoclinic.org/diseases-conditions/cholangiocarcinoma/symptoms-causes/syc-20352408
14. Ilyas SI, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterol-ogy. 2013;145(6):1215-1229. doi:10.1053/j.gastro.2013.10.013
15. Cancer statistics for the year 2020: An overview - PubMed. Accessed October 9, 2024. https://pubmed.ncbi.nlm.nih.gov/33818764/
16. Global Cancer Observatory. Accessed August 28, 2024. https://gco.iarc.who.int/en
17. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
18. Gravitz L. Liver cancer. Nature. 2014;516(7529):S1-S1. doi:10.1038/516S1a
19. Cen W, Li J, Tong C, et al. Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2. J Cancer. 2021;12(12):3448-3457. doi:10.7150/jca.55627
20. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in Liver Disease. 2017;21(1):1-20. doi:10.1016/j.cld.2016.08.001
21. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. European Journal of Cancer. 2022;161:108-118. doi:10.1016/j.ejca.2021.11.023
22. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147-R1151. doi:10.1016/j.cub.2017.09.019
23. Cancer-related inflammation. Accessed August 28, 2024. https://air.unimi.it/handle/2434/145688
24. Cellular fatty acid metabolism and cancer - PubMed. Accessed August 28, 2024. https://pubmed.ncbi.nlm.nih.gov/23791484/
25. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(5):400-410, 413.
26. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013
27. Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141-162. doi:10.1038/s41573-021-00339-6
28. The Heterogeneity of Liver Cancer Metabolism. In: Le A, ed. The Heterogeneity of Cancer Metabolism. Springer International Publishing; 2021:127-136. doi:10.1007/978-3-030-65768-0_9
29. Wang Y, Yu W, Li S, Guo D, He J, Wang Y. Acetyl-CoA Carboxylases and Diseases. Front Oncol. 2022;12:836058. doi:10.3389/fonc.2022.836058
30. Luo DX, Tong DJ, Rajput S, et al. Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential. Recent Patents on Anti-Cancer Drug Discovery. 7(2):168-184. doi:10.2174/157489212799972918
31. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models - PubMed. Accessed October 9, 2024. https://pubmed.ncbi.nlm.nih.gov/27643638/
32. Schug ZT, Vande Voorde J, Gottlieb E. The metabolic fate of acetate in cancer. Nat Rev Cancer. 2016;16(11):708-717. doi:10.1038/nrc.2016.87
33. Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006;66(10):5287-5294. doi:10.1158/0008-5472.CAN-05-1489
34. Razumilava N, Gores GJ. Cholangiocarcinoma. The Lancet. 2014;383(9935):2168-2179. doi:10.1016/S0140-6736(13)61903-0
35. Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280. doi:10.1038/nrgastro.2016.51
36. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.
37. Liver cancer - Symptoms and causes. Mayo Clinic. Accessed October 2, 2024. https://www.mayoclinic.org/diseases-conditions/liver-cancer/symptoms-causes/syc-20353659
38. Liver Cancer: Symptoms, Signs, Causes & Treatment. Cleveland Clinic. Accessed October 2, 2024. https://my.clevelandclinic.org/health/diseases/9418-liver-cancer
39. Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25(5):400-410, 413.
40. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200
41. Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism. 2016;23(1):27-47. doi:10.1016/j.cmet.2015.12.006
42. GEPIA (Gene Expression Profiling Interactive Analysis). Accessed August 28, 2024. http://gepia.cancer-pku.cn/index.html